The Seed Investor News Roundup

Read our Investor Dashboard on OTC:ABCCF TSX.v ABCN

There will be a sudden wave of "Marijuana Millionaires" in 2017 - will you be one?

Read the Investors Guide To Newly Emerging Marijuana Markets

How These Canadian Companies Are Preparing for Potential $6 Billion Market

The Canadian recreational cannabis market is one of the most exciting markets in the world. We look at how companies are positioning themselves, and identify one small recreational brand to have a look at.

Peace Naturals Receives Dealer's License Allowing for the Exportation of New Product Categories

Cronos Group Inc. (TSXV: MJN) (OTC – Nasdaq Int'l Designation: PRMCF) is pleased to announce that Peace Naturals Project Inc., a licensed producer wholly owned by the Company, has just obtained a Dealer's License pursuant to the Controlled Drugs and Substances Act under Health Canada.

CanniMed Therapeutics Announces Continuation of Discussions with Aurora

CanniMed Therapeutics Inc. (TSX:CMED) announces that it is continuing to discuss terms of a possible transaction with Aurora Cannabis Inc.

Namaste Receives Health Canada Confirmation of Readiness

Namaste Technologies Inc. (CSE:N) (FRA:M5BQ) (OTCMKTS:NXTTF) is pleased to announce that Health Canada’s Office of Medical Cannabis has provided the Company with a Confirmation of Readiness for a license under Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”) for the Company’s wholly owned subsidiary, Cannmart Inc.

Abattis Partners with Vancouver-Based Craft Brewer to Develop Hemp-Infused, Cannabinoid-Rich, THC-Free Craft Beer

Abattis Bioceuticals Corp. (CSE:ATT) (OTC:ATTBF) is pleased to announce the formation of a new partnership with Faculty Brewing Co., a Vancouver-based craft brewery, to develop a hemp-infused, cannabinoid-rich, THC-free craft beer.

Please see full disclaimers on the TheSeedInvestor.com website applicable to all content provided by TSI, wherever published or re-published: http://theseedinvestor.com/about/disclaimerDisclaimer.

This news release/advertorial is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed on this website unless you can afford to lose your entire investment. Also, investing in small-cap and micro-cap securities is highly speculative and carries an extremely high degree of risk. This website makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. Compensation: A thirty-six-thousand-dollar investor relations budget is being managed by The Seed Investor. Any funds leftover after expenses for research, overhead, advertising and public relations related to InMed Pharmaceuticals Inc. (ticker symbol (CSE: IN; OTCQB: IMLFF) will be considered profit. The Seed Investor and/or entities related to The Seed Investor hold shares in (CSE: IN; OTCQB: IMLFF) and intend to sell those shares. Please review all investment decisions with a licensed investment advisor.

TheSeedInvestor.com
9375 E Shea Blvd Ste 100
Scottsdale 85260

info@theseedinvestor.com

To keep receiving emails from us, please add us to your address book.